Brief: 4D Molecular Therapeutics Receives EMA Priority Medicines (Prime) Designation For 4D-150 Clinical-Stage Genetic Medicine For Treatment Of Wet AMD
23/10/2023 14:01
Oct 23 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION
FOR
4D-150 CLINICAL-STAGE GENETIC MEDICINE FOR TREATMENT OF WET AMD
Source text for Eikon: ID:nGNX7QD16K
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings